



**UNIVERSITI PUTRA MALAYSIA**

***NEUROPROTECTIVE AND NEUROREGENERATIVE PROPERTIES  
OF HARUAN (CHANNA STRIATUS) TRADITIONAL FORMULATION***

**MOHD AFFENDI BIN MOHD SHAFRI**

**FPSK(p) 2012 23**

**NEUROPROTECTIVE AND  
NEUROREGENERATIVE PROPERTIES OF  
HARUAN (*CHANNA STRIATUS*) TRADITIONAL  
FORMULATION**

**MOHD AFFENDI BIN MOHD SHAFRI**

**DOCTOR OF PHILOSOPHY  
UNIVERSITI PUTRA MALAYSIA**

**2012**

**NEUROPROTECTIVE AND  
NEUROREGENERATIVE PROPERTIES OF  
HARUAN (*CHANNA STRIATUS*) TRADITIONAL  
FORMULATION**

**By**

**MOHD AFFENDI BIN MOHD SHAFRI**

**Thesis submitted to the School of Graduate Studies,  
Universiti Putra Malaysia, in Fulfilment of the  
Requirement for the Degree of Doctor of Philosophy**

**August 2012**

**Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of the requirement for the degree of Doctor in Philosophy in Physiology**

**NEUROPROTECTIVE AND NEUROREGENERATIVE PROPERTIES OF HARUAN (*CHANNA STRIATUS*) TRADITIONAL FORMULATION**

**By**

**MOHD AFFENDI BIN MOHD SHAFRI**

**August 2012**

**Chair: Prof. Abdul Manan Mat Jais, PhD**

**Faculty: Fakulti Perubatan dan Sains Kesihatan**

Neurodegenerative conditions continue to affect a large number of people. Despite numerous studies carried out in the last few decades, no effective treatment has been found and current management of neurodegenerative conditions are not effective, marred by side-effects, costly and could only provide symptomatic alleviations. Haruan or *Channa striatus*, is rich in many important amino acids and fatty acids, which may act as suitable pharmacological modulators to neuron cells as they have potential to cross the blood-brain barrier efficiently and have anti-oxidative action and may trigger neurite growth receptor on neuron cell's surface. The neuroprotective and neuroregenerative effects of haruan traditional formulation (HTF) on PC12 cell line, an established cell line used for studying neurite outgrowth, was first studied to see its effect of cell growth behaviour, morphology and neurite outgrowth. From the study, HTF appears to influence neurite outgrowth, cell morphology and growth behaviour in PC12 cells in concentration dependent manner. It was found that HTF at 100  $\mu$ L in the serum rich assay was most effective in providing protection against cell death as well as in

stimulating greatest neurite extension ( $p < 0.001$ , one way ANOVA with Tukey's post hoc test). Next, in *in vivo* experiment using Sprague Dawley rats, the effect of HTF on rats' nose-dipping and rearing behaviours in neuroprotective and neuroregenerative assays, in which two neurodegenerative agents, ketamine and methamphetamine given intraperitoneally, 4 four times a day at 2 hour interval at different doses were used, was studied using a hole board maze. It was found that HTF could provide some neuroprotective ( $p < 0.01$  for the nose dip and  $p < 0.05$  for rearing; one way ANOVA with Tukey's post hoc analysis) and neuroregenerative ( $p < 0.001$  for both nose dip and rearing; one way ANOVA with Tukey's post hoc analysis) effects on rats behaviour for the LEK group only. Consequent change in hippocampus was assessed by further analyses of the hippocampus CA3 region in terms of live neuron cell count, and pathological change in the overall structural integrity by staining the hippocampal sections using cresyl violet stains. Cell counting was done using Java-Installed Image J software, images were captured using a Nikon Ti Inverted Fluorescent Microscope and Imaging software and data was statistically analysed using a Sigma Plot 11.0 for Windows. It was found that the best effect in term of preservation of structural integrity and regeneration of live cell number ( $p < 0.001$  one way ANOVA with Tukey's post hoc analysis) was in the LEK. The HTF is less able to produce positive changes in the methamphetamine-treated groups which may be used to identify the mode of actions of HTF's neurorestorative mechanism in future research. In view of other results however correlation between functional, numerical and structural changes is not straightforward. Although there is evidence of neuroprotective and neuroregenerative effects, HTF must be studied further for more conclusive evidence.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah PhD Fisiologi

**UPAYA PERLINDUNGAN DAN PENJANAAN SEMULA NEURON OLEH  
FORMULASI HARUAN (*CHANNA STRIATUS*) SECARA TRADISIONAL**

**Oleh**

**MOHD AFFENDI BIN MOHD SHAFRI**

**Ogos 2012**

**Pengerusi: Prof. Abdul Manan Mat Jais, PhD**

**Fakulti: Fakulti Perubatan dan Sains Kesihatan**

Keadaan degenerasi neuron terus memberi kesan kepada sebilangan besar penduduk dunia. Walaupun banyak kajian yang dijalankan dalam beberapa dekad yang lalu, tiada rawatan yang berkesan telah ditemui. Ubatan semasa mempunyai kesan-kesan sampingan, mahal dan hanya boleh mengurangkan gejala penyakit bukan merawatnya. Haruan atau *Channa striatus*, adalah kaya dengan asid amino dan asid lemak penting, yang boleh bertindak sebagai modular farmakologi yang sesuai untuk sel-sel neuron kerana mempunyai potensi untuk merentasi sempadan otak-sistem pembuluh darah secara cekap, mempunyai tindakan anti-oksidatif dan kebolehan untuk mencetuskan reseptor pertumbuhan neurite pada permukaan sel neuron. Kesan neuroprotektif dan neuroregenerasi formulasi tradisional haruan (HTF) diuji ke atas sel PC12, yang digunakan untuk mengkaji neurite untuk melihat kesan ke atas tingkah laku pertumbuhan sel, morfologi dan pertumbuhan neurite. Dari kajian tersebut, HTF muncul untuk mempengaruhi pertumbuhan neurite, morfologi sel dan tingkah laku pertumbuhan

dalam PC12 sel-sel bergantung kepada kepekatan berbeza. HTF pada 100  $\mu$ L dalam cerakin kaya serum adalah yang paling berkesan dalam menyediakan perlindungan terhadap kematian sel serta dalam merangsang pertumbuhan neurite ( $p < 0.001$ , ANOVA sehalu dengan ujian post hoc Tukey's). Seterusnya, di dalam eksperimen in vivo menggunakan tikus Sprague Dawley, kesan HTF pada frekuensi haiwan itu memasukkan hidungnya ke dalam lubang dan berdiri di atas kaki belakangnya dalam cerakin neuroprotektif dan neuroregenerasi, di mana dua ejen neurodegenerasi, ketamin dan methamphetamine, diberikan secara intraperitoneal, empat kali sehari dengan 2 jam selang pada dos yang berbeza telah digunakan, dan dikaji menggunakan peralatan Papan Berlubang. Dapatan menunjukkan bahawa HTF boleh menyebabkan kesan neuroprotektif ( $p < 0.01$  untuk frekuensi memasukkan hidung ke dalam lubang dan  $p < 0.05$  untuk kelakuan berdiri di atas kaki belakang; one-way ANOVA dengan analisis post hoc Tukey's) dan neuroregenerasi ( $p < 0.001$  untuk kelakuan memasukkan hidung ke dalam lubang dan berdiri di atas kaki belakang; one-way ANOVA dengan analysis post hoc Tukey's) untuk kumpulan LEK sahaja. Perubahan dalam rantau CA3 hippocampus telah dinilai selanjutnya dari segi kiraan sel neuron hidup, dan perubahan patologi dalam integriti keseluruhan struktur dengan menggunakan pewarna ungu cresyl. Pengiraan dilakukan dengan bantuan perisian Image J dengan Java, imej ditangkap menggunakan perisian Ti Nikon Inverted Microscope Pendarfluor dan Pengimejan dan data telah dianalisis menggunakan Sigma Plot 11.0 untuk Windows. Kajian ini mendapati bahawa kesan terbaik dalam jangka pemeliharaan integriti struktur dan pertumbuhan semula bilangan sel hidup ( $p < 0.001$  one-way ANOVA dengan analisis post hoc Tukey) adalah dalam LEK. Secara keseluruhannya, perubahan positif didapati berlaku kepada neurodegenerasi yang disebabkan oleh ketamine dan kesan positif

terhadap perubahan neurodegenerasi methamphetamine adalah kurang dan ini boleh digunakan untuk mengenalpasti dengan jelas lagi mekanisma neurorestoratif HTF di dalam kajian mendatang. Dengan mengambil kira keputusan lain dalam kajian ini, hubungkait antara perubahan berfungsi, bilangan sel dan integriti struktur tidak mudah untuk dirungkai. Walaupun kajian ini menunjukkan terdapat bukti kesan neuroprotektif dan neuroregenerasi pada HTF, HTF perlu dikaji lagi untuk keterangan lebih muktamad.





## **ACKNOWLEDGEMENT**

All praise is to Allah, and prayers and blessing to the Prophet Muhammad s.a.w., his Household, his Companions, and those who follow him s.a.w. until the Day of Judgment.

I thank my Supervisor, Prof. Abdul Manan bin Mat Jais, the co-supervisors, Prof. Kim Min Kyu and Assoc. Prof. Dr. Hairuszah Ithnin from Universiti Putra Malaysia, and Asst. Prof. Dr. Juliana Md. Jaffri, from International Islamic University Malaysia for their help.

I also thank my wife, Farahidah Mohamed for kind attention and understanding throughout the length of the study. I also appreciate the presence of my kids, Muhammad Fariduddin Affendi and Farah ‘Aliyyah, whose faces and laughter always brighten my days.

I thank also my parents, siblings and relatives for their everlasting support, to my research assistants for help rendered, to International Islamic University of Malaysia, Kementerian Pengajian Tinggi Malaysia, Agensi Anti-Dadah Kebangsaan and Polis di-Raja Malaysia for providing necessary funds and help.

Last but not least, I thank those individuals not mentioned here who have also supported me in many respects until the completion of the project. Allah rewards those who show kindness.

**THANK YOU.**

## Approval Sheet 1

I certify that a Thesis Examination Committee has met on 8/8/2012) to conduct the final examination of (MOHD AFFENDI BIN MOHD SHAFRI) on his (or her) thesis entitled "**NEUROPROTECTIVE AND NEUROREGENERATIVE PROPERTIES OF HARUAN (CHANNA STRIATUS) FORMULATION**" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the PhD in Physiology.

Members of the Thesis Examination Committee were as follows:

**Dr. Zainul Amiruddin Zakaria, PhD**

Associate Prof.

Fakulti Perubatan dan Sains Kesihatan  
Universiti Putra Malaysia  
(Chairman)

**Dr. Mohd Roslan Sulaiman, PhD**

Professor

Fakulti Perubatan dan Sains Kesihatan  
Universiti Putra Malaysia  
(Internal Examiner)

**Dr. Sabrina Sukardi, PhD**

Associate Professor

Fakulti Perubatan dan Sains Kesihatan  
Universiti Putra Malaysia  
(Internal Examiner)

**Dr. Zullies Ikawati, PhD**

Professor

Department of Pharmacy, Faculty of Pharmacy  
Universiti Gadjad Mada, Yogyakarta  
Indonesia  
(External Examiner)

---

**SEOW HENG FONG, PhD**

Professor and Deputy Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date:

## Approval Sheet 2

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of **Doctor of Philosophy**. The members of the Supervisory Committee were as follows:

**Prof. Dr. Abdul Manan Mat Jais, PhD**

Department of Biomedical Science,  
Fakulti Perubatan dan Sains Kesihatan,  
Universiti Putra Malaysia  
(Chairman)

**Dr. Kim Min Kyu, PhD**

Institute of Bioscience  
Universiti Putra Malaysia  
(Member)

**Assoc. Prof. Dr. Hajah Hairuszah Ithnin,**

Department of Histopathology and Cytology,  
Fakulti Perubatan dan Sains Kesihatan, Universiti Putra Malaysia  
(Member)

**Asst. Prof. Dr. Juliana Md. Jaffri, PhD**

Department of Pharmaceutical Technology,  
Kulliyah of Pharmacy, International Islamic University Malaysia.  
(Member)

---

**BUJANG BIN KIM HUAT, PhD**

Professor and Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date:

## **DECLARATION**

I declare that the thesis is my original work except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously, and is not concurrently, submitted for any other degree at Universiti Putra Malaysia or at any other institution.

---

**MOHD AFFENDI BIN MOHD SHAFRI**

Date: 8 August 2012

## LIST OF TABLES

TABLE		Page
2.1	Treatment of Parkinson's disease that target the dopaminergic system: its tolerability and efficacy (Adapted from Mueller, 2012)	21
2.2	Seizure of selected drugs in Malaysia between 2005-2009	23
2.3	Important amino acids and fatty acids in different parts of <i>Channa striatus</i> extract	40
2.4	Examples of mazes used to test lab animals and their purposes	54
3.1	Example of triplicates in 12 well plates	68
3.2	Description of cell death score (CDS), expressed as mean value of triplicates sample, in PC12 treatment with different HTF dose. (Adapted from Vyas et al., 2002)	69
3.3	Description of change in morphology score (CMS), expressed as mean value of triplicates sample, in PC12 treatment with different HTF dose. (Adapted from Radio & Mundy, 2008)	70
4.1	Parameters tested for holeboard maze test and their definition. (Adapted from Johansson & Hansen, 2001)	106
4.2	Groups in the neuroprotective assay	113
4.3	Groups in the neuroregenerative assay	115
5.1	Groups in the neuroprotective assay	159
5.2	Groups in the neuroregenerative assay	160
5.3	Description of pathological score in cresyl violet-stained sections	165

## LIST OF FIGURES

FIGURE		Page
2.1	The pathogenesis of neurodegeneration formed by factors which lead to the generation of neuro-degeneration as well as factors that block regeneration may be reversed by HTF (red) which ameliorates effects of proinflammatory markers and unblocks axonal regeneration. [NOS: nitric oxide synthase TNF: tumour necrosis factor; IL: interleukin; IFN: interferons; ROS: reactive oxygen species; COX: cyclooxygenase; PGs: prostaglandins] (Adapted from Wang et al, 2006.)	12
2.2	Schematic diagram to illustrate the action of ketamine of NMDA receptor involves the blockage of the open channel and the reduction of frequency of channel opening. (Adapted from Hustveit et al, 1995); NR1 (NMDA Receptor subunit 1); Ket (Ketamine)	25
2.3	An adult haruan typically measures 15-30 cm in length from head to tail. [From ibenkztrology.blogspot.com]	34
2.4	The holeboard maze (16 x 3 cm-in-diameter holes, 40 cm x 40 cm dimension) (loaned by Kulliyyah of Science, IIUM) used in this study stands at 18 cm above the table level and comes equipped with a counter unit, connected together by a cable of convenient length	55
2.5	The hippocampus and its main regions. (CA: cornu ammonis. DG: dentate gyrus)	57
3.1	Culture protocol for in vitro neurorestorative assays of HTF in PC12 cell line	66
3.2	Step-by-step procedures involve in culturing, treating and analysing PC12 cells treated with HTF in various bio-assays	67
3.3	The amount of PC12 cell death, expressed in % in 1 mm <sup>2</sup> area in culture well, at 24, 48 and 72 hours in different treatment in a serum-rich assay; HTF (haruan traditional formulation)	79
3.4	The amount of PC12 cell death, expressed in % in 1 mm <sup>2</sup> area	

	in culture well, at 24, 48 and 72 hours in different treatment in a serum-free assay; HTF (haruan traditional formulation)	80
3.5	The number of PC12 cell showing polarity, expressed in % in 1 mm <sup>2</sup> area in culture well, at 24, 48 and 72 hours in different treatment in a serum-rich assay; HTF (haruan traditional formulation)	81
3.6	The number of PC12 cell showing polarity, expressed in % in 1 mm <sup>2</sup> area in culture well, at 24, 48 and 72 hours in different treatment in a serum-free assay; HTF (haruan traditional formulation)	82
3.7	The mean neurite length (µm) in PC12 at 24, 48 and 72 hours in different treatment in a serum-rich assay; HTF (haruan traditional formulation)	83
3.8	The mean neurite length (µm) in PC12 at 24, 48 and 72 hours in different treatment in a serum-free assay; HTF (haruan traditional formulation)	84
3.9	Negative control of PC12 cells in serum-rich assay showing aggregating behaviour of PC12 cells. Solid arrow is showing healthy, growing cell. Dotted arrow is showing a dead cell	85
3.10	Positive control of PC12 cells in 1 ml cAMP in serum rich assay showing segregating behaviour. Arrow is showing a cell with neurite extension	86
3.11	PC12 cells treated with 100 µL of HTF in serum-rich showing segregating multipolar cells with axonal extension interacting with each other. Arrow is showing a multipolar cell with very strong neurite extension	87
3.12	PC12 cells in serum-rich medium treated with 100 µL HTF showing greatest multiaxonal cell (solid arrow). Bipolar cells (dotted arrow) and dead cells could also be observed (dashed arrow)	88
3.13	PC12 cells treated with 200 µL HTF, in serum-rich assay showing cells with multipolarity and neurite extension (arrow)	89
3.14	PC12 cells treated with 400 µL HTF in serum-rich assay shows an increasingly bipolar character. Arrow is pointing to a bipolar cell	90

3.15	Bipolar PC12 cells treated with 800 $\mu$ L HTF in serum-rich assay (solid arrow) showing bipolar cells and many dead cells (dotted arrow)	91
3.16	Negative control of PC12 cells in serum-free assay showing aggregating behaviour of PC12 cells showing high number of dead cells (arrow) at 24 hour	92
3.17	Positive control in serum free assay showing high amount of cell death (arrow) at 72 hours	93
3.18	100 $\mu$ L of HTF in serum free assay showing high amount of cell death at 72 hours but surviving cells able to show neurite outgrowth with several presented with multipolarity (arrow)	94
3.19	200 $\mu$ L of HTF in serum free assay showing high amount of cell death (solid arrow) at 72 hours but surviving cells able to show neurite outgrowth with several polarized cells (dotted arrow)	95
3.20	400 $\mu$ L of HTF in serum free assay showing high amount of cell death (solid arrow) at 72 hours but surviving cells able to show neurite outgrowth with several polarized cells (dotted arrows)	96
3.21	PC12 cells grown in serum-free assay and treated with 800 $\mu$ L HTF, showing bipolarity (solid arrow) and lesser amount of cell debris (dotted arrow)	97
3.22	Neuronal polarities in normal stages of development of neuronal cells. (Adapted from de Anda et al., 2008)	99
3.23	Concentration-dependent change in cell death, morphology and neurite outgrowth in HTF-treated, serum-rich group	103
3.24	Concentration-dependent change in cell death, morphology and neurite outgrowth in HTF-treated, serum-free group	104
4.1	Design of test room and placement of hole board and observers	111
4.2	Time points for neurobehavioural test (NBT) using hole board maze for neuroprotective assay. (T0 = NBT done before exposure to HTF, T1= NBT after completion of HTF exposure, T2 = NBT before first exposure to drug, T3 = NBT after completion of drug exposure)	112
4.3	Time points for neurobehavioural test (NBT) using hole board maze for neuroregenerative assay. (T0 = NBT done before exposure to drug, T1= NBT 12 hours after completion of drug exposure and before first HTF exposure, T2 = NBT after first	



	HTF exposure; T3 = NBT after end of HTF exposure)	114
4.4	The effect of HTF (haruan traditional formulation) and short exposure to ketamine (SEK) in neuroprotective (NProt) assay on the frequency of nose dip in Sprague Dawley rats at different time points; KET (ketamine)	129
4.5	The effect of HTF (haruan traditional formulation) and long exposure to ketamine (LEK) in neuroprotective (NProt) assay on the frequency of nose dip in Sprague Dawley rats at different time points; KET (ketamine)	130
4.6	The effect of HTF (haruan traditional formulation) and short exposure to ketamine (SEK) in neuroprotective (NProt) assay on the frequency of rearing in Sprague Dawley rats at different time points; KET (ketamine)	131
4.7	The effect of HTF (haruan traditional formulation) and long exposure to ketamine (LEK) in neuroprotective (NProt) assay on the frequency of rearing in Sprague Dawley rats at different time points; KET (ketamine)	132
4.8	The effect of HTF (haruan traditional formulation) and short exposure to methamphetamine (SEM) in neuroprotective (NProt) assay on the frequency of nose dip in Sprague Dawley rats at different time points; MET (methamphetamine)	133
4.9	The effect of HTF (haruan traditional formulation) and long exposure to methamphetamine (LEM) in neuroprotective (NProt) assay on the frequency of nose dip in Sprague Dawley rats at different time points; MET (methamphetamine)	134
4.10	The effect of HTF (haruan traditional formulation) and short exposure to methamphetamine (SEM) in neuroprotective (NProt) assay on the frequency of rearing in Sprague Dawley rats at different time points; MET (methamphetamine)	135
4.11	The effect of HTF (haruan traditional formulation) and long exposure to methamphetamine (LEM) in neuroprotective (NProt) assay on the frequency of rearing in Sprague Dawley rats at different time points; MET (methamphetamine)	136
4.12	The effect of HTF (haruan traditional formulation) and short exposure to ketamine (SEK) in neuroregenerative (NReg) assay on the frequency of nose dip in Sprague Dawley rats at different time points; KET (ketamine)	137

4.13	The effect of HTF (haruan traditional formulation) and long exposure to ketamine (LEK) in neuroregenerative (NReg) assay on the frequency of nose dip in Sprague Dawley rats at different time points; KET (ketamine)	138
4.14	The effect of HTF (haruan traditional formulation) and short exposure to ketamine (SEK) in neuroregenerative (NReg) assay on the frequency of rearing in Sprague Dawley rats at different time points; KET (ketamine)	139
4.15	The effect of HTF (haruan traditional formulation) and long exposure to ketamine (LEK) in neuroregenerative (NReg) assay on the frequency of rearing in Sprague Dawley rats at different time points; KET (ketamine)	140
4.16	The effect of HTF (haruan traditional formulation) and short exposure to methamphetamine (SEM) in neuroregenerative (NReg) assay on the frequency of nose dip in Sprague Dawley rats at different time points; MET (methamphetamine)	141
4.17	The effect of HTF (haruan traditional formulation) and long exposure to methamphetamine (LEM) in neuroregenerative (NReg) assay on the frequency of nose dip in Sprague Dawley rats at different time points; MET (methamphetamine)	142
4.18	The effect of HTF (haruan traditional formulation) and short exposure to methamphetamine (SEM) in neuroregenerative (NReg) assay on the frequency of rearing in Sprague Dawley rats at different time points; MET (methamphetamine)	143
4.19	The effect of HTF (haruan traditional formulation) and long exposure to methamphetamine (LEM) in neuroregenerative (NReg) assay on the frequency of rearing in Sprague Dawley rats at different time points; MET (methamphetamine)	144
5.1	Transcardial perfusion performed by first making a Y-shape incision to reveal the heart and then creating an inlet at the left ventricle and an outlet at the right atrium to perfuse and preserve the animal with formalin internally. (RA: right atrium; LA: left atrium; RV: right ventricle; LV: left ventricle)	162
5.2	The effect of short ketamine exposure and HTF treatment of live cells count per 1 mm <sup>2</sup> area of CA3 in neuroprotective assay. HTF: Haruan traditional formulation; SEK: short ketamine exposure, Ket: ketamine only 1 day exposure	169
5.3	The effect of long ketamine exposure and HTF treatment of live	

	cells count per 1 mm <sup>2</sup> area of CA3 in neuroprotective assay. HTF: Haruan traditional formulation; LEK: long ketamine exposure, Ket: ketamine only 5 days exposure	170
5.4	The effect of short methamphetamine exposure and HTF treatment of live cells count per 1 mm <sup>2</sup> area of CA3 in neuroprotective assay. HTF: Haruan traditional formulation; SEM: short methamphetamine exposure, Meth: methamphetamine only 1 day exposure	171
5.5	The effect of long methamphetamine exposure and HTF treatment of live cells count per 1 mm <sup>2</sup> area of CA3 in neuroprotective assay. HTF: Haruan traditional formulation; LEM: long methamphetamine exposure, Meth: methamphetamine only 5 days exposure	172
5.6	The effect of short ketamine exposure and HTF treatment of live cells count per 1 mm <sup>2</sup> area of CA3 in neuroregenerative assay. HTF: Haruan traditional formulation; SEK: short ketamine exposure, Ket: ketamine only 1 day exposure	174
5.7	The effect of long ketamine exposure and HTF treatment of live cells count per 1 mm <sup>2</sup> area of CA3 in neuroregenerative assay. HTF: Haruan traditional formulation; LEK: long ketamine exposure, Ket: ketamine only 5 days exposure	175
5.8	The effect of short methamphetamine exposure and HTF treatment of live cells count per 1 mm <sup>2</sup> area of CA3 in neuroregenerative assay. HTF: Haruan traditional formulation; SEM: short methamphetamine exposure, Meth: methamphetamine only 1 day exposure	176
5.9	The effect of long methamphetamine exposure and HTF treatment of live cells count per 1 mm <sup>2</sup> area of CA3 in neuroregenerative assay. HTF: Haruan traditional formulation; LEK: long methamphetamine exposure, Meth: methamphetamine only 5 days exposure	177
5.10	Cresyl violet stained sections of CA3 of the hippocampus in the neuroprotective assay at 100 x magnification (A: SEK – Saline only; B: HTF only; C: Ketamine 1 day ; D: Ketamine for 5 days; E: Methamphetamine for 1 day; F: Methamphetamine for 5 days. Arrow showing live, non-pycnotic cells)	178
5.11	Cresyl violet stained sections of CA3 of the hippocampus in the neuroprotective assay at 100 x magnification (A: SEK – Short exposure ketamine; B: LEK - Long exposure ketamine;	

C: SEM – Short exposure methamphetamine; D: LEM – Long exposure methamphetamine). (Arrow showing live, non-pycnotic cells)

179

5.12

Cresyl violet stained sections of CA3 of the hippocampus in the neuroregenerative assay at 100 x magnification. (A: SEK – Short exposure ketamine; B: LEK – Long exposure ketamine; C: SEM - Short exposure methamphetamine; D: LEM - Long exposure methamphetamine) (Arrow showing live, non-pycnotic cells)

180



## LIST OF ABBREVIATIONS

ACE	angiotensin converting enzyme
AMP	adenosine monophosphate
BDNF	brain-derived neurotrophic factor
BSE	bovine spongiform encephalopathy
Ca <sup>2+</sup>	calcium
CA3	cornu ammonis
cAMP	cyclic adenosine monophosphate
cGMP	cyclic guanosine monophosphate
CNS	central nervous system
COX	cyclooxygenase
CPK	creatine phosphokinase
CPK-MB	creatine phosphokinase-MB
CTF-II	cardiotoxic factor-II
DFPL	double fractionated palm olein
DHA	docosahexaenoic acid
DMSO	dimethyl sulphic oxide
DNA	deoxyribonucleic acid
EMEM	Eagle's Minimum Essential Medium
EPA	eicosapentaenoic acid
EPO	erythropoietin
ERK	extracellular-signal regulated kinase
FAMA	Federal Agricultural Marketing Agency
FBS	foetal bovine serum

GABA	gamma-aminobutyric acid
H <sub>2</sub> O <sub>2</sub>	hydrogen peroxide
HTF	haruan traditional formulation
IFN- $\gamma$	interferon gamma
IL	interleukin
KMnO <sub>4</sub>	potassium permanganate
LA	left atrium
LEK	long-exposure ketamine
LEM	long-exposure methamphetamine
LV	left ventricle
Mn <sup>2+</sup>	manganase
MPDV	methylenedioxypropyvalerone
MTT	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolinbromide
NADA	National Anti Drug Agency
NaOH	sodium hydroxide
NBT	neurobehavioural test
NGF	neuronal growth factor
NVM	non-vitamin/mineral
NMDA	N-methyl-D-aspartate
NO	nitric oxide
NOS	nitric oxide synthase
NR1	NMDA-receptor 1
PBS	phosphate buffer solution
PC12	phaechromocytoma 12
PDRM	Polis di-Raja Malaysia

PG	prostaglandin
PKC	protein kinase C
PKG	protein kinase G
RA	right atrium
RBC	red blood cell
RNA	ribonucleic acid
RNS	reactive nitrogen species
ROS	reactive oxygen species
RV	right ventricle
SEK	short-exposure ketamine
SEM	short-exposure methamphetamine
SFSE	shol fish skin extract
SVZ	supraventricular zone
TNF- $\alpha$	tumour necrosis factor- $\alpha$
Trypsin-EDTA	trypsin-ethylenediaminetetraacetic acid
TIP	transferring-insulin-progesterone
VM	vitamin and mineral
WBC	white blood cell

# TABLE OF CONTENT

	Page
<b>ABSTRACT</b>	<b>ii</b>
<b>ABSTRAK</b>	<b>v</b>
<b>ACKNOWLEDGEMENTS</b>	<b>viii</b>
<b>APPROVAL</b>	<b>ix</b>
<b>DECLARATION</b>	<b>xiii</b>
<b>LIST OF TABLES</b>	<b>xiv</b>
<b>LIST OF FIGURES</b>	<b>xvi</b>
<b>LIST OF ABBREVIATIONS</b>	<b>xxxii</b>

## CHAPTER

<b>1</b>	<b>INTRODUCTION</b>	
1.1	Background of study	1
1.2	Problem statement	7
1.3	Research questions	7
1.4	Objectives of study	8
1.4.1	General objectives	8
1.4.2	Specific objectives	8
1.5	Hypotheses	9
<b>2</b>	<b>LITERATURE REVIEW</b>	<b>10</b>
2.1	Neurodegeneration	10
2.1.1	Definition and causes	10
2.1.2	Neurodegenerative diseases	13
2.2	Alternative strategies against neurodegeneration	31
2.2.1	The role of exogenous non-drug substance from traditional medicine for neuroprotection and neuroregeneration functions	32



2.3	Haruan	33
2.3.1	Physiological and Pharmacological Profile and Traditional Uses	33
2.3.2	Haruan Extracts	36
2.3.3	Channa Striatus and the rationale as a Neurorestorative Agent	49
2.4	Cell Culture using PC12 cells	52
2.5	Neurobehavioural Study	53
2.6	Brain Histology and Staining	56
2.6.1	Hippocampus	56
2.6.2	Cresyl Violet Stain	57
3	<b>IN VITRO STUDY USING PC12 CELL LINE TO DETERMINE THE POTENTIAL OF HARUAN TRADITIONAL EXTRACT (HTF) AS NEURO-PROTECTIVE AND/OR NEUROREGENERATIVE AGENT</b>	59
3.1	Introduction	59
3.2	Materials	60
3.3	Methods	60
3.3.1	Location of Study	60
3.3.2	Formulation of Haruan Traditional Formulation (HTF)	61
3.3.3	In vitro Biological Assay Using PC12 Cell Line	62
3.3.4	Statistical analysis	71
3.4	Results	71
3.4.1	The Effect of HTF in Inducing Change in Cell Survival	72
3.4.2	The Effect of HTF in Inducing Change in Cell Morphology	73

3.4.3	The Effect of HTF in Inducing Change in Neurite Length	76
3.5	Discussion	98
3.5.1	HTF's neuroprotective role	98
3.5.2	HTF's neurite generation capacity	100
3.6	Conclusion	103
4	<b>IN VIVO STUDY TO ASSESS NEUROBEHAVIOURAL EFFECTS FOLLOWING TREATMENT OF HTF IN BRAIN DAMAGE-INDUCED IN SPRAGUE DAWLEY RATS</b>	105
4.1	Introduction	105
4.2	Materials	107
4.3	Methods	107
4.3.1	Location of Study	107
4.3.2	Extraction of Haruan Traditional Extract (HTF)	107
4.3.3	Preparation of Dose of Ketamine	107
4.3.4	Preparation of Dose of Methamphetamine	108
4.3.5	In vivo Neurobehavioural Test (NBT)	109
4.3.6	Ethical Statement	116
4.3.7	Statistical Analyses	116
4.4	Results	116
4.4.1	Neuroprotective Assay	116
4.4.2	Neuroregenerative Assay	123
4.5	Discussion	145
4.5.1	Behavioural Parameters	145
4.5.2	Neuroprotective Effects of HTF	147

4.5.3	Neuroregenerative Effects of HTF	150
4.6	Conclusion	153
5	<b>HISTOLOGICAL STUDY TO ASSESS NEUROPROTECTIVE AND NEUROREGENERATIVE EFFECTS OF HTF AGAINST NEURODEGENERATIVE DAMAGE OF KETAMINE AND METHAMPHETAMINE IN SPRAGUE DAWLEY RATS</b>	155
5.1	Introduction	155
5.2	Materials	156
5.3	Methods	157
5.3.1	Sprague Dawley rats	157
5.3.2	Transcardial Perfusion	161
5.3.3	Brain Dissection	161
5.3.4	Preparation of Hippocampal Brain Sections	162
5.3.5	Cresyl Violet Stain	163
5.3.6	Cell Counting	164
5.3.7	Statistical Analysis	164
5.4	Results	165
5.4.1	Pathological score	166
5.4.2	Live cell count	167
5.5	Discussion	181
5.5.1	The Neuroprotective and Active Effects of HTF on Ketamine-induced Neurodegeneration	181
5.5.2	The Neuroprotective and Neuroregenerative Effects of HTF on Methamphetamine-induced Neurodegeneration	183
5.6	Conclusion	185

<b>6</b>	<b>SUMMARY, RECOMMENDATION FOR FUTURE RESEARCH AND CONCLUSION</b>	<b>187</b>
6.1	Summary	187
6.2	The Possible Mechanism of Effect of HTF on Neuroprotective and Neuroregenerative Functions	190
6.3	Recommendation for future research	195
6.4	Conclusion	200
	<b>REFERENCES</b>	<b>201</b>
	<b>APPENDIX A</b>	<b>241</b>
	<b>APPENDIX B</b>	<b>242</b>
	<b>BIODATA OF STUDENT</b>	<b>243</b>
	<b>LIST OF PUBLICATIONS</b>	<b>244</b>